Vu Trang T, Gooderham Melinda, Papp Kim
a Faculty of Medicine , University of Toronto , Toronto , Canada.
b Skin Centre for Dermatology , Peterborough , Canada.
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1423-1433. doi: 10.1080/17512433.2016.1242409. Epub 2016 Oct 11.
The interleukin (IL)-17 family of cytokines has emerged as an important pro-inflammatory mediator of psoriasis and psoriatic arthritis (PsA). Ixekizumab is an IL17A inhibitor that has been approved for the treatment of chronic plaque psoriasis. Phase III studies of ixekizumab in treating of PsA demonstrated promise by minimizing disease severity and progression. Areas covered: This review focuses on the biologic properties, pharmacokinetics and key clinical trial results that demonstrated the safety and efficacy of ixekizumab in treating psoriatic disease. Expert commentary: Ixekizumab is a biologic that has been approved for the treatment of chronic plaque psoriasis. With respect to safety, ixekizumab is generally well tolerated with injection-site reactions, nasopharyngitis, and upper respiratory tract infections being the most common adverse events. Most patients with anti-drug antibodies have low antibody titer levels resulting in no meaningful interference in clinical response to ixekizumab.
白细胞介素（IL）-17细胞因子家族已成为银屑病和银屑病关节炎（PsA）的一种重要促炎介质。司库奇尤单抗是一种IL-17A抑制剂，已被批准用于治疗慢性斑块状银屑病。司库奇尤单抗治疗PsA的III期研究通过将疾病严重程度和进展降至最低显示出前景。涵盖领域：本综述重点关注司库奇尤单抗治疗银屑病疾病的生物学特性、药代动力学和关键临床试验结果，这些结果证明了其安全性和有效性。专家评论：司库奇尤单抗是一种已被批准用于治疗慢性斑块状银屑病的生物制剂。在安全性方面，司库奇尤单抗总体耐受性良好，注射部位反应、鼻咽炎和上呼吸道感染是最常见的不良事件。大多数抗药物抗体患者的抗体滴度水平较低，不会对司库奇尤单抗的临床反应产生有意义的干扰。
